Results 21 to 30 of about 28,679 (139)

Self-amplifying RNA vaccines for infectious diseases [PDF]

Gene Therapy, 2020
Vaccinology is shifting toward synthetic RNA platforms which allow for rapid, scalable, and cell-free manufacturing of prophylactic and therapeutic vaccines. The simple development pipeline is based on in vitro transcription of antigen-encoding sequences or immunotherapies as synthetic RNA transcripts, which are then formulated for delivery.
Bloom, Kristie, van den Berg, Fiona, Arbuthnot, Patrick   +2 more
openaire   +2 more sources

Reinventing the nucleic acid vaccine with self-amplifying RNA [PDF]

Retrovirology, 2012
Background Self-amplifying RNAs (replicons) of positive-strand viruses such as alphaviruses are potentially safe and useful vectors for delivering vaccine antigens. We previously showed that recombinant alphavirus replicon particles (VRP), used in prime-boost regimen with Env in MF59 protein protected rhesus macaques against mucosal challenge with ...
Geall AJ, Otten GR, Hekele A, Bogers W, Oostermeijer H, Mooij P, Gerrit K, Verschoor E, Banerjee K, Cu Y, Beard CW, Brito LA, Ulmer JB, Mandl CW, Barnett SW   +14 more
doaj   +2 more sources

Conjugation of Mannans to Enhance the Potency of Liposome Nanoparticles for the Delivery of RNA Vaccines

Pharmaceutics, 2021
Recent approval of mRNA vaccines to combat COVID-19 have highlighted the potential of this platform. Lipid nanoparticles (LNP) is the delivery vehicle of choice for mRNA as they prevent its enzymatic degradation by encapsulation.
Roshan Goswami, Derek T. O’Hagan, Roberto Adamo, Barbara C. Baudner   +3 more
doaj   +1 more source

A Phase I/II Clinical Trial of Intradermal, Controllable Self-Replicating Ribonucleic Acid Vaccine EXG-5003 against SARS-CoV-2

Vaccines, 2023
mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have played a key role in reducing morbidity and mortality from coronavirus disease 2019 (COVID-19).
Takenao Koseki, Mayumi Teramachi, Minako Koga, Minoru S. H. Ko, Tomokazu Amano, Hong Yu, Misa Amano, Erica Leyder, Maria Badiola, Priyanka Ray, Jiyoung Kim, Akihiro C. Ko, Achouak Achour, Nan-ping Weng, Takumi Imai, Hisako Yoshida, Satsuki Taniuchi, Ayumi Shintani, Hidetsugu Fujigaki, Masashi Kondo, Yohei Doi   +20 more
doaj   +1 more source

Nonviral delivery of self-amplifying RNA vaccines [PDF]

Proceedings of the National Academy of Sciences, 2012
Despite more than two decades of research and development on nucleic acid vaccines, there is still no commercial product for human use. Taking advantage of the recent innovations in systemic delivery of short interfering RNA (siRNA) using lipid nanoparticles (LNPs), we developed a self-amplifying RNA vaccine.
Andrew J, Geall, Ayush, Verma, Gillis R, Otten, Christine A, Shaw, Armin, Hekele, Kaustuv, Banerjee, Yen, Cu, Clayton W, Beard, Luis A, Brito, Thomas, Krucker, Derek T, O'Hagan, Manmohan, Singh, Peter W, Mason, Nicholas M, Valiante, Philip R, Dormitzer, Susan W, Barnett, Rino, Rappuoli, Jeffrey B, Ulmer, Christian W, Mandl   +18 more
openaire   +2 more sources

The next generation of RNA vaccines: self-amplifying RNA [PDF]

The Biochemist, 2021
The global COVID-19 pandemic has brought tremendous momentum to the field of messenger RNA (mRNA) vaccines. The advantages of this vaccine platform, such as rapid development and high efficacy, resulted in mRNA vaccines being the first approved vaccines against COVID-19.
openaire   +1 more source

Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies

Frontiers in Immunology, 2022
We assessed if immune responses are enhanced in CD-1 mice by heterologous vaccination with two different nucleic acid-based COVID-19 vaccines: a next-generation human adenovirus serotype 5 (hAd5)-vectored dual-antigen spike (S) and nucleocapsid (N ...
Adrian Rice, Mohit Verma, Emily Voigt, Peter Battisti, Sam Beaver, Sierra Reed, Kyle Dinkins, Shivani Mody, Lise Zakin, Shiho Tanaka, Brett Morimoto, C. Anders Olson, Elizabeth Gabitzsch, Jeffrey T. Safrit, Patricia Spilman, Corey Casper, Corey Casper, Patrick Soon-Shiong   +17 more
doaj   +1 more source

Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses

Vaccines, 2023
Although conventional vaccine approaches have proven to be successful in preventing infectious diseases in past decades, for vaccine development against emerging/re-emerging viruses, one of the main challenges is rapid response in terms of design and ...
Yalan Liu, Yuncheng Li, Qinxue Hu
doaj   +1 more source

Design-of-experiments in vitro transcription yield optimization of self-amplifying RNA [PDF]

F1000Research, 2021
Background: Self-amplifying RNA (saRNA) vaccines are able to induce a higher antigen-specific immune response with a more cost-effective and rapid production process compared to plasmid DNA vaccines. saRNAs are synthesized through in vitro transcription (IVT); however ...
Karnyart Samnuan, Anna K. Blakney, Paul F. McKay, Robin J. Shattock   +3 more
openaire   +1 more source

Self-Amplifying RNA Viruses as RNA Vaccines

International Journal of Molecular Sciences, 2020
Single-stranded RNA viruses such as alphaviruses, flaviviruses, measles viruses and rhabdoviruses are characterized by their capacity of highly efficient self-amplification of RNA in host cells, which make them attractive vehicles for vaccine development.
openaire   +2 more sources